CSI-Glucagon for Prevention of Hypoglycemia in Children With Congenital Hyperinsulinism
Status:
Completed
Trial end date:
2018-10-01
Target enrollment:
Participant gender:
Summary
This is a Phase 2, multi-center, randomized, placebo-controlled, double-blind trial with
open-label follow-up designed to assess the efficacy of Xeris Glucagon delivered as a
continuous subcutaneous infusion to prevent hypoglycemia with lower intravenous glucose
infusion rates in children < 1 year of age with congenital hyperinsulinism.
Phase:
Phase 2
Details
Lead Sponsor:
Xeris Pharmaceuticals
Collaborator:
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)